| 1 |
Singer M，Deutschman CS，Seymour CW，et al.The Third International Consensus Definitions for Sepsis and Septic Shock （Sepsis-3） ［J］.JAMA，2016，315（8）：801-810.
|
| 2 |
Fleischmann-Struzek C，Mellhammar L，Rose N，et al.Incidence and mortality of hospital- and ICU-treated sepsis：results from an updated and expanded systematic review and meta-analysis ［J］.Intensive Care Med，2020，46（8）：1552-1562.
|
| 3 |
Almalki WH.The sepsis induced defective aggravation of immune cells：a translational science underling chemico-biological interactions from altered bioenergetics and/or cellular metabolism to organ dysfunction ［J］.Mol Cell Biochem，2021，476（6）：2337-2344.
|
| 4 |
Jiang W，Li X，Wen M，et al.Increased percentage of PD-L1（+） natural killer cells predicts poor prognosis in sepsis patients：a prospective observational cohort study ［J］.Crit Care，2020，24（1）：617.
|
| 5 |
Schöniger S，Jasani B.The PD-1/PD-L1 pathway：a perspective on comparative immuno-oncology ［J］.Animals （Basel），2022，12（19）：2661.
|
| 6 |
Kythreotou A，Siddique A，Mauri FA，et al.PD-L1 ［J］.J Clin Pathol，2018，71（3）：189-194.
|
| 7 |
Wherry EJ，Kurachi M.Molecular and cellular insights into T cell exhaustion ［J］.Nat Rev Immunol，2015，15（8）：486-499.
|
| 8 |
Gao Y，Yang J，Cai Y，et al.IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling ［J］.Int J Cancer，2018，143（4）：931-943.
|
| 9 |
Boomer JS，To K，Chang KC，et al.Immunosuppression in patients who die of sepsis and multiple organ failure ［J］.JAMA，2011，306（23）：2594-2605.
|
| 10 |
Roquilly A，McWilliam HEG，Jacqueline C，et al.Local modulation of antigen-presenting cell development after resolution of pneumonia induces long-term susceptibility to secondary infections ［J］.Immunity，2017，47（1）：135-147.e135.
|
| 11 |
Beltrán-García J，Osca-Verdegal R，Jávega B，et al.Characterization of early peripheral immune responses in patients with sepsis and septic shock ［J］.Biomedicines，2022，10（3）：525.
|
| 12 |
Xu R，Liu X，Li A，et al.c-Met up-regulates the expression of PDL1 through MAPK/NF-κBp65 pathway ［J］.J Mol Med （Berl），2022，100（4）：585-598.
|
| 13 |
Fernandes RA，Su L，Nishiga Y，et al.Immune receptor inhibition through enforced phosphatase recruitment ［J］.Nature，2020，586（7831）：779-784.
|
| 14 |
Chemnitz JM，Parry RV，Nichols KE，et al.SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation，but only receptor ligation prevents T cell activation ［J］.J Immunol，2004，173（2）：945-954.
|
| 15 |
Marasco M，Berteotti A，Weyershaeuser J，et al.Molecular mechanism of SHP2 activation by PD-1 stimulation ［J］.Sci Adv，2020，6（5）：eaay4458.
|
| 16 |
Patsoukis N，Li L，Sari D，et al.PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2 ［J］.Mol Cell Biol，2013，33（16）：3091-3098.
|
| 17 |
Wang JF，Wang YP，Xie J，et al.Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis ［J］.Blood，2021，138（9）：806-810.
|
| 18 |
Liu J，Song K，Lin B，et al.HMGB1 promotes neutrophil PD-L1 expression through TLR2 and mediates T cell apoptosis leading to immunosuppression in sepsis ［J］.Int Immunopharmacol，2024，133：112130.
|
| 19 |
Hussain SM，Kansal RG，Alvarez MA，et al.Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression［J］.Cell Oncol （Dordr），2021，44（3）：673-687.
|
| 20 |
Josefowicz SZ，Lu LF，Rudensky AY.Regulatory T cells：mechanisms of differentiation and function ［J］.Annu Rev Immunol，2012，30：531-564.
|
| 21 |
Grover P，Goel PN，Greene MI.Regulatory T cells：regulation of identity and function ［J］.Front Immunol，2021，12：750542.
|
| 22 |
Che YM，Zhang Y，Li M，et al.In vitro and in vivo effect of PD-1/PDL1 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal meningitis ［J］.J Cell Biochem，2018，119（4）：3044-3057.
|
| 23 |
Shao R，Fang Y，Yu H，et al.Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients：a prospective cohort study ［J］.Crit Care，2016，20（1）：124.
|
| 24 |
Xia Q，Wei L，Zhang Y，et al.Immune checkpoint receptors Tim-3 and PD-1 regulate monocyte and T lymphocyte function in septic patients［J］.Mediators Inflamm，2018，2018：1632902.
|
| 25 |
Hokama LT，Veiga ADM，Menezes MCS，et al.Endothelial injury in COVID-19 and septic patients ［J］.Microvasc Res，2022，140：104303.
|
| 26 |
Cahill PA，Redmond EM.Vascular endothelium - Gatekeeper of vessel health ［J］.Atherosclerosis，2016，248：97-109.
|
| 27 |
Yang X，Chang Y，Wei W.Endothelial dysfunction and inflammation：immunity in rheumatoid arthritis ［J］.Mediators Inflamm，2016，2016：6813016.
|
| 28 |
Smeding L，Plötz FB，Groeneveld AB，et al.Structural changes of the heart during severe sepsis or septic shock ［J］.Shock，2012，37（5）：449-456.
|
| 29 |
Opal SM，van der Poll T.Endothelial barrier dysfunction in septic shock ［J］.J Intern Med，2015，277（3）：277-293.
|
| 30 |
Hutchins NA，Wang F，Wang Y，et al.Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1 ［J］.J Leukoc Biol，2013，94（5）：963-970.
|
| 31 |
Zhao S，Gao J，Li J，et al.Correction to：PD-L1 regulates inflammation in LPS-induced lung epithelial cells and vascular endothelial cells by interacting with the HIF-1α signaling pathway ［J］.Inflammation，2022，45（2）：931-932.
|
| 32 |
Lomas-Neira J，Monaghan SF，Huang X，et al.Novel role for PD-1：PD-L1 as mediator of pulmonary vascular endothelial cell functions in pathogenesis of indirect ARDS in mice ［J］.Front Immunol，2018，9：3030.
|
| 33 |
Wang Z，Guo Z，Wang X，et al.Inhibition of EZH2 ameliorates sepsis acute lung injury （SALI） and non-small-cell lung cancer （NSCLC）proliferation through the PD-L1 pathway ［J］.Cells，2022，11（24）：3958.
|
| 34 |
Curran CS，Busch LM，Li Y，et al.Anti-PD-L1 therapy does not improve survival in a murine model of lethal Staphylococcus aureus pneumonia ［J］.J Infect Dis，2021，224（12）：2073-2084.
|
| 35 |
Liu S，Xie J，Duan C，et al.ADAR1 inhibits macrophage apoptosis and alleviates sepsis-induced liver injury through miR-122/BCL2A1 signaling ［J］.J Clin Transl Hepatol，2024，12（2）：134-150.
|
| 36 |
Li M，Song K，Huang X，et al.GDF-15 prevents LPS and D-galactosamine-induced inflammation and acute liver injury in mice［J］.Int J Mol Med，2018，42（3）：1756-1764.
|
| 37 |
Liang X，Li T，Zhou Q，et al.Mesenchymal stem cells attenuate sepsisinduced liver injury via inhibiting M1 polarization of Kupffer cells ［J］.Mol Cell Biochem，2019，452（1-2）：187-197.
|
| 38 |
Wang F，Huang X，Chung CS，et al.Contribution of programmed cell death receptor （PD）-1 to Kupffer cell dysfunction in murine polymicrobial sepsis ［J］.Am J Physiol Gastrointest Liver Physiol，2016，311（2）：G237-245.
|
| 39 |
Triantafyllou E，Gudd CL，Mawhin MA，et al.PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury ［J］.J Clin Invest，2021，131（4）.
|
| 40 |
Lu Y，Wang G，Li C.Expression of peripheral monocytic programmed death ligand-1 in severe sepsis combined with HBV-related cirrhosis.A pilot observational study ［J］.Cent Eur J Immunol，2021，46（2）：217-224.
|
| 41 |
Gómez H，Kellum JA.Sepsis-induced acute kidney injury ［J］.Curr Opin Crit Care，2016，22（6）：546-553.
|
| 42 |
Kawamoto E，Masui-Ito A，Eguchi A，et al.Integrin and PD-1 ligand expression on circulating extracellular vesicles in systemic inflammatory response syndrome and sepsis ［J］.Shock，2019，52（1）：13-22.
|
| 43 |
Hu YM，Hsiung YC，Pai MH，et al.Glutamine administration in early or late septic phase downregulates lymphocyte PD-1/PD-L1 expression and the inflammatory response in mice with polymicrobial sepsis ［J］.JPEN J Parenter Enteral Nutr，2018，42（3）：538-549.
|
| 44 |
Xu J，Ma X，Yu K，et al.Lactate up-regulates the expression of PD-L1 in kidney and causes immunosuppression in septic Acute Renal Injury［J］.J Microbiol Immunol Infect，2021，54（3）：404-410.
|
| 45 |
Patera AC，Drewry AM，Chang K，et al.Frontline science：defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1 ［J］.J Leukoc Biol，2016，100（6）：1239-1254.
|
| 46 |
Hotchkiss RS，Colston E，Yende S，et al.Immune checkpoint inhibition in sepsis：a phase 1b randomized，placebo-controlled，single ascending dose study of antiprogrammed cell death-ligand 1 antibody （BMS-936559） ［J］.Crit Care Med，2019，47（5）：632-642.
|
| 47 |
Hotchkiss RS，Colston E，Yende S，et al.Immune checkpoint inhibition in sepsis：a Phase 1b randomized study to evaluate the safety，tolerability，pharmacokinetics，and pharmacodynamics of nivolumab［J］.Intensive Care Med，2019，45（10）：1360-1371.
|
| 48 |
Watanabe E，Nishida O，Kakihana Y，et al.Pharmacokinetics，pharmacodynamics，and safety of Nivolumab in patients with sepsisinduced immunosuppression：a multicenter，open-label phase 1/2 study［J］.Shock，2020，53（6）：686-694.
|
| 49 |
Valentine C，Bergerat A.Immunoprofiling determines survival and guides therapy in sepsis ［J］.J Immunol，2016，196（Suppl 1）：194-196.
|
| 50 |
Chan KK，Bass AR.Autoimmune complications of immunotherapy：pathophysiology and management ［J］.BMJ，2020，369：m736.
|